Drug profile · INN
levobunolol hydrochloride
AKBETA
levobunolol hydrochloride (AKBETA) is a beta-2 adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — levobunolol hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
levobunolol hydrochloride (AKBETA) is a beta-2 adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is levobunolol hydrochloride?
levobunolol hydrochloride (AKBETA) is a beta-2 adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for levobunolol hydrochloride?
AKBETA is a marketed brand name for levobunolol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levobunolol hydrochloride?
levobunolol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.